Working... Menu
Trial record 12 of 123 for:    IK

Evaluate the Pharmacokinetics of Simvastatin When Coadministered With PEX168 in Healthy Adult Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02447601
Recruitment Status : Completed
First Posted : May 19, 2015
Last Update Posted : January 24, 2017
Information provided by (Responsible Party):
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Brief Summary:

To assess the effect of PEX168 doses on the pharmacokinetics of simvastatin(as determined by simvastation acid) in healthy subjects.

To assess the safety of single doses of simvastation administered with and without PEX168

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus Drug: PEX168 Drug: Simvastatin Phase 1

Detailed Description:

This was an open-label, sequential, single-center study that evaluated the pharmacokinetics of simvastatin when coadministered with PEX168 in healthy adult subjects. The total duration of each subject's participation in the study was approximately 10 weeks, which included up to a 14-day Screening Period, a 34-day Treatment Period, and an approximately 4-week Follow-up Period.

Center: This study was conducted at a single site in Shanghai Mental Health Center (SMHC)of China Treatment.All subjects receives a single 40-mg oral dose of simvastatin on Day 1 followed by 5 weekly 200μg doses of PEX168 injected subcutaneously beginning on Day 3 and a second single 40-mg oral dose of simvastatin on Day 33.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: An Open-label,Sequential,Single-site Study to Evaluate the Pharmacokinetics of Simvastatin When Coadministered With Polyethylene Glycol Loxenatide (PEX168) in Healthy Adult Subjects
Actual Study Start Date : March 30, 2015
Actual Primary Completion Date : May 14, 2015
Actual Study Completion Date : August 11, 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Simvastatin and PEX168(200µg)
Simvastatin: 40mg, oral Administration. PEX 168: 200µg,injected subcutaneously,once a week.
Drug: PEX168
200µg,injected subcutaneously,once a week.
Other Name: Polyethylene Glycol Loxenatide

Drug: Simvastatin
40mg,oral,two times
Other Name: Shujiangzhi

Primary Outcome Measures :
  1. Plasma concentrations of simvastatin and simvastatin acid. [ Time Frame: Baseline to Day34 ]
    Plasma concentrations of simvastatin and simvastatin acid, and to calculate the pharmacokinetic parameters: Tmax, Cmax, AUC0-t, AUC0-∞, λz, t1 / 2, Vd / F, CL / F, etc.

Secondary Outcome Measures :
  1. Incidence of adverse events and serious adverse events [ Time Frame: Baseline to Day67 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

An individual who met all of the following criteria was eligible for the study.

  1. Healthy male aged 18 to 45 years (including both ends) at the time of signing the informed consent.
  2. Weighing not less than 50kg,Body Mass Index (BMI)of 18 to 25kg/m2.
  3. No history of cardiovascular, liver, kidney, gastrointestinal, neuropsychiatric and other diseases, no history of drug allergy.
  4. Capable of giving written informed consent, which included compliance with the requirements and restrictions listed in the consent form.

Exclusion Criteria:

  1. Known for any study drug allergy (PEX168, simvastatin) or similar drug allergy (GLP-1 receptor agonists, GLP-1 analogue, statins) or allergic constitution;
  2. Having Alcohol and drug abuse within first 6 months before screening;
  3. Smoked within 3 months before screening;
  4. Received GLP-1 receptor agonists, GLP-1 analogs, DPP-IV inhibitors, or any other similar structure drug for treatment before screening;
  5. Following a thorough medical examination, clinically significant abnormalities were found;
  6. In screening period, blood pressure greater than 140 / 90mmHg, retest after diagnosis or pulse rate is higher than 100bpm person;
  7. In screening period, ECG QTc> 450ms, diagnosed after retest;
  8. In screening period, serum creatinine or urine protein is abnormal, and were determined to be clinically significant by the investigator;
  9. In screening period, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), γ- glutamate GGT (γ-GT), total bilirubin (Tbil) is greater than the normal range limit, and investigator determines to have clinical significance;
  10. In screening period, creatine kinase (CK) exceeds the upper limit of the normal range, and judged by the investigator to be clinical significant;
  11. In screening period, having thyroid dysfunction;
  12. Before screening there is a history of medullary thyroid cancer;
  13. Having any surgery (including the impact of gastric emptying of gastrointestinal surgery) within 6 months before screening;
  14. Participate in blood donation and donation amount ≥400ml within three months before screening, or who participate in blood donation or blood transfusion within a month;
  15. Using any of the tested drugs may affect prescription drugs, nonprescription drugs, herbs, food (such as grapefruit juice) or food supplements persons 2 weeks before screening;
  16. Drinking medication or caffeine-containing xanthine food and beverage (listed in annex 3), strenuous exercise, or other effects of drug absorption, distribution, metabolism, excretion and other factors 2 days before screening.
  17. Any clinically significant by the investigator determined that acute diseases before Screening occurred within a month too;
  18. There is a history of pancreatitis or acute pancreatitis before screening;
  19. Having dyslipidemia, coronary heart disease, and a history of high cholesterol before screening.
  20. There are lung disease histories, history of chronic liver and gallbladder disease, cholecystitis history, history of bladder disease, a history of colon inflammation before screening.
  21. Within three months before screening participated in any drug or medical device clinical trials were (including placebo);
  22. Hepatitis B surface antigen, hepatitis C antibody, HIV antibody, syphilis antibody test positive;
  23. Reluctant to take effective contraceptive methods of contraception. During the trial, there was family planning within six months after their spouses during the trial or the last dose (first 33 days);
  24. The investigator believe that any situation that might lead to any subject cannot be completed or to the subject of this study bring significant risk.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02447601

Layout table for location information
China, Shanghai
Shanghai Mental Health Center (SMHC)
Shanghai, Shanghai, China, 200122
Sponsors and Collaborators
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Layout table for investigator information
Principal Investigator: Huafang Li, MD Shanghai Mental Health Center (SMHC)

Layout table for additonal information
Responsible Party: Jiangsu Hansoh Pharmaceutical Co., Ltd. Identifier: NCT02447601     History of Changes
Other Study ID Numbers: PEX168-Ik
PEX168-Ik ( Other Identifier: JiangsuHaosen )
First Posted: May 19, 2015    Key Record Dates
Last Update Posted: January 24, 2017
Last Verified: May 2015
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors